Gliatilin, 1000mg/4ml 4ml ampoules, 3pcs

Composition

Active ingredient:  

choline alfoscerate 1000 mg;

Auxiliary substances:

water for injection

Pharmacological action

Gliatilin is neuroprotective.

Pharmacodynamics

Improves the transmission of nerve impulses in cholinergic neurons; positively affects the plasticity of neuronal membranes and the function of receptors. Improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.

It has a preventive and corrective effect on such pathogenetic factors of involutional psychoorganic syndrome as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Experimental studies have shown that Gliatilin stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

When ingested, it is broken down by enzymes into choline and glycerophosphate.

Gliatilin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and has a positive effect on neurotransmission, on the other hand, glycerophosphate participates in the synthesis of phosphatidylcholine (a membrane phospholipid), as a result, both have a positive effect on membrane elasticity and on the function of receptors, which improves synaptic transmission.

Thus, pharmacodynamic studies have shown that Gliatilin acts on synaptic, including cholinergic neurotransmission; plasticity of the neural membrane; and receptor function.

Pharmacokinetics

Absorption by mouth — 88%; easily penetrates through the BBB, accumulates mainly in the brain (the concentration in the brain reaches 45% of the level in the blood), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

It does not affect the reproductive cycle, does not have teratogenic and mutagenic effects.

Indications

• acute period of TBI mainly stem from the level of the lesion (impaired consciousness, coma, focal poliserna symptoms, symptoms of lesions of the brain stem);
• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency such as primary and secondary disorders of mental functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, ability to concentrate;
• changes in emotional and behavioral sphere: emotional lability, increased irritability, loss of interest, senile pseudomeningocele;
• multi-infarct dementia.

Use during pregnancy and lactation

Gliatilin is contraindicated during pregnancy, lactation, and childhood.

Contraindications

Hypersensitivity to the components of the drug.

Side effects

Nausea (as a consequence of dopaminergic activation), in this case, the dose of the drug should be reduced. Possible allergic reactions.

Interaction

The drug interaction of Gliatilin has not been established.

How to take, course of use and dosage

Adults with acute conditions:  iv — at a dose of 1000 mg / day (1 ampoule) or iv-1000-3000 mg/day.

When administered intravenously, the contents of 1 ampoule (4 ml) are diluted in 50 ml of saline solution, the infusion rate is 60-80 drops per minute.

The duration of treatment is usually 10 days, but if necessary, treatment can be continued until positive dynamics appear and it is possible to switch to oral capsules.

Overdose

Symptoms:  nausea.

If this symptom occurs, it is recommended to reduce the dose of the drug.

Special instructions

In experimental studies, no mutagenic effect of the drug has been established.

– Influence on the ability to drive vehicles and manage mechanisms Gliatilin does not affect the patient’s ability to engage in potentially dangerous activities.

Form of production

Solution for intravenous and intramuscular use

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

5 years

Active ingredient

Choline alfoscerate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Description

For adults as directed by your doctor

Indications

Alzheimer’s Disease, Acquired Dementia, Stroke Effects, Mental Disorders